APA

Kümler I., Balslev E., Stenvang J., Brünner N., Ejlertsen B., Jakobsen E. H. & Nielsen D. L. (20191223). Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. : BMC cancer.

Chicago

Kümler Iben, Balslev Eva, Stenvang Jan, Brünner Nils, Ejlertsen Bent, Jakobsen Erik Hugger and Nielsen Dorte Lisbet. 20191223. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. : BMC cancer.

Harvard

Kümler I., Balslev E., Stenvang J., Brünner N., Ejlertsen B., Jakobsen E. H. and Nielsen D. L. (20191223). Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. : BMC cancer.

MLA

Kümler Iben, Balslev Eva, Stenvang Jan, Brünner Nils, Ejlertsen Bent, Jakobsen Erik Hugger and Nielsen Dorte Lisbet. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. : BMC cancer. 20191223.